全文获取类型
收费全文 | 8767篇 |
免费 | 710篇 |
国内免费 | 35篇 |
学科分类
医药卫生 | 9512篇 |
出版年
2023年 | 84篇 |
2022年 | 48篇 |
2021年 | 267篇 |
2020年 | 170篇 |
2019年 | 218篇 |
2018年 | 312篇 |
2017年 | 182篇 |
2016年 | 240篇 |
2015年 | 286篇 |
2014年 | 398篇 |
2013年 | 498篇 |
2012年 | 767篇 |
2011年 | 758篇 |
2010年 | 386篇 |
2009年 | 411篇 |
2008年 | 612篇 |
2007年 | 643篇 |
2006年 | 604篇 |
2005年 | 663篇 |
2004年 | 525篇 |
2003年 | 527篇 |
2002年 | 422篇 |
2001年 | 44篇 |
2000年 | 31篇 |
1999年 | 56篇 |
1998年 | 75篇 |
1997年 | 55篇 |
1996年 | 33篇 |
1995年 | 38篇 |
1994年 | 32篇 |
1993年 | 20篇 |
1992年 | 12篇 |
1991年 | 14篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 6篇 |
1986年 | 8篇 |
1985年 | 2篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 2篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1974年 | 2篇 |
1973年 | 6篇 |
1972年 | 3篇 |
1961年 | 2篇 |
1893年 | 1篇 |
排序方式: 共有9512条查询结果,搜索用时 31 毫秒
1.
Li Dong Mari Nygård Nathalie C. Støer Ole Klungsøyr Bo T. Hansen 《International journal of cancer. Journal international du cancer》2023,153(2):399-406
Human papillomavirus (HPV) vaccine effectiveness may differ between settings. Here we present the first real-world effectiveness study of HPV vaccination on high-grade cervical lesions from Norway, among women who received HPV vaccine outside the routine program. We performed an observational study of all Norwegian women born 1975 to 1996 and retrieved individual data from nationwide registries on HPV vaccination status and incidence of histologically verified high-grade cervical neoplasia during 2006 to 2016. We estimated the incidence rate ratio (IRR) and 95% confidence intervals (CI) for vaccination vs no vaccination by Poisson regression stratified by age at vaccination <20 years and ≥20 years. The cohort consisted of 832 732 women, of which 46 381 (5.6%) received at least one dose of HPV vaccine by the end of 2016. The incidence rate of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increased with age regardless of vaccination status and was highest at age 25 to 29, at 637/100 000 among unvaccinated women, 487/100 000 among women vaccinated before age 20 and 831/100 000 among women vaccinated at age 20 or older. The adjusted IRR of CIN2+ between vaccinated and unvaccinated women was 0.62 (95% CI: 0.46-0.84) for women vaccinated below age 20, and 1.22 (95% CI: 1.03-1.43) for women vaccinated at age 20 or older. These findings indicate that HPV vaccination among women too old to be eligible for routine HPV vaccination is effective among women who are vaccinated below age 20 but may not have the desired impact among women who are vaccinated at age 20 or older. 相似文献
2.
Kayla Ann Andrews Joel S. Owen James McCarthy David Wesche Nathalie Gobeau Thaddeus H. Grasela Jrg J. Mhrle 《CTS Clinical and Translational Science》2021,14(2):712
Volunteer infection studies using the induced blood stage malaria (IBSM) model have been shown to facilitate antimalarial drug development. Such studies have traditionally been undertaken in single‐dose cohorts, as many as necessary to obtain the dose‐response relationship. To enhance ethical and logistic aspects of such studies, and to reduce the number of cohorts needed to establish the dose‐response relationship, we undertook a retrospective in silico analysis of previously accrued data to improve study design. A pharmacokinetic (PK)/pharmacodynamic (PD) model was developed from initial fictive‐cohort data for OZ439 (mixing the data of the three single‐dose cohorts as: n = 2 on 100 mg, 2 on 200 mg, and 4 on 500 mg). A three‐compartment model described OZ439 PKs. Net growth of parasites was modeled using a Gompertz function and drug‐induced parasite death using a Hill function. Parameter estimates for the PK and PD models were comparable for the multidose single‐cohort vs. the pooled analysis of all cohorts. Simulations based on the multidose single‐cohort design described the complete data from the original IBSM study. The novel design allows for the ascertainment of the PK/PD relationship early in the study, providing a basis for rational dose selection for subsequent cohorts and studies. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THIS STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
3.
4.
5.
6.
7.
8.
9.